Bemiparin sodium

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Bemiparin sodium
Heparin General Structure V.1.svg
Clinical data
Trade namesBadyket, Ivor, Hibor, Zibor, others
AHFS/Drugs.comInternational Drug Names
Routes of
Subcutaneous injection (except for haemodialysis)
ATC code
Pharmacokinetic data
Bioavailability96% (estimated)
Elimination half-life5–6 hours
CAS Number
  • none
Chemical and physical data
Molar mass3600 g/mol (average)
 ☒N☑Y (what is this?)  (verify)

Bemiparin (trade names Ivor and Zibor, among others) is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).[1]

Medical uses[edit]

Bemiparin is used for the prevention of thromboembolism after surgery, and to prevent blood clotting in the extracorporeal circuit in haemodialysis.[2]


The medication is contraindicated in patients with a history of heparin-induced thrombocytopenia with or without disseminated intravascular coagulation; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or pancreas impairment; and acute or subacute bacterial endocarditis.[2]


No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, aspirin and other NSAIDs, antiplatelet drugs, and corticosteroids.[2]


Like semuloparin, bemiparin is classified as an ultra-LMWH because of its low molecular mass of 3600 g/mol on average.[3] (Enoxaparin has 4500 g/mol.) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.[4]


  1. ^ Chapman TM, Goa KL (2003). "Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis". Drugs. 63 (21): 2357–77. doi:10.2165/00003495-200363210-00009. PMID 14524738.
  2. ^ a b c Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2018. Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen.
  3. ^ Planès, A. (2003). "Review of bemiparin sodium – a new second-generation low molecular weight heparin and its applications in venous thromboembolism". Expert Opinion on Pharmacotherapy. 4 (9): 1551–1561. doi:10.1517/14656566.4.9.1551. PMID 12943485.
  4. ^ Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H. L. N.; Viskov, C. (2011). "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin". Thrombosis Research. 128 (4): 361–367. doi:10.1016/j.thromres.2011.03.001. PMID 21458847.

External links[edit]